Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05052801
Title Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Amgen
Indications

stomach cancer

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin

Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | CAN | BEL

Additional content available in CKB BOOST